How Target Type Shapes the Best Nanobody Discovery Strategy

The best nanobody discovery strategy depends on what the target is, how it is presented, and how the final binder will be used. A soluble protein, a membrane receptor, a toxin, and a multi-protein complex each create different risks for antigen preparation, screening, and validation. I recommend defining the target’s native state and intended veterinary application before selecting an immunization or library-screening route. This helps ensure that candidates are assessed against the biologically relevant target—not just an easy-to-produce version of it.

Check now

Key Takeaways

For soluble proteins, prioritize correct folding, relevant domains, and controls that distinguish specific binding from tag or carrier recognition.
For membrane proteins and complexes, preserve native structure and use a screening format that reflects the intended biological context.
For toxins and pathogen targets, define whether the goal is detection, neutralization, or another function before screening.
In veterinary projects, species, sample matrix, and assay conditions can change which nanobody is the most useful candidate.
Agree on validation criteria and deliverables with your discovery partner before starting the project.

Start With the Target’s Biological Form

A target’s identity alone does not provide enough information to design a discovery campaign. The same protein may appear as a soluble domain, a membrane-bound receptor, a processed fragment, or part of a larger complex. Each form exposes different binding surfaces and may behave differently in an assay. I therefore begin by asking which molecular form the nanobody must recognize in the final application.

Soluble proteins and individual domains

Soluble proteins are often the most straightforward targets when a stable, well-characterized antigen is available. I would check whether the reagent is full-length or truncated, how it is expressed, whether it carries a purification tag, and whether its folding or glycosylation is important. Screening against only a tagged fragment can enrich binders that recognize the tag or an artificial surface rather than the intended protein.

For veterinary diagnostics, a soluble antigen may be used to detect a pathogen, a host response marker, or a disease-associated protein. The discovery plan should reflect the actual assay format, such as an immobilized capture assay or a solution-phase binding test. Where feasible, I recommend including an untagged target, an irrelevant protein control, or a second target preparation to help assess specificity.

Membrane proteins and cell-surface targets

Membrane proteins can be difficult to represent with purified antigen because their structure may depend on a lipid environment, partner proteins, or the orientation of multiple domains. A purified fragment can still be useful, but it may not display the same accessible surfaces as the intact protein on a cell. When the intended application involves cell recognition, I would consider screening or validation on cells expressing the target, alongside appropriate negative-control cells.

For veterinary research, this can matter when a project focuses on receptors on immune cells, infected cells, or other tissue-associated targets. The screening design should distinguish target-dependent binding from nonspecific cell-surface adherence. If the nanobody is intended to work under physiological conditions, validation may include testing at 37 °C; this is an example condition, not a universal requirement, and should be matched to the assay and use case.

Multi-protein complexes and conformational epitopes

Some targets are functional only as part of a complex or in a particular conformational state. In these projects, a binder discovered against an isolated subunit may fail to recognize the assembled complex, while a binder to the complex may not bind the free subunit. I recommend identifying whether the project needs recognition of a shared subunit, a complex-specific interface, or a state-dependent epitope before choosing the screening antigen.

Where a complex is involved, use the most relevant stable presentation available and confirm candidate binding in a second format when possible. This can help reveal whether a result depends on immobilization or on a structure that is not present in the intended sample. The appropriate confirmation method depends on the target and application; no single assay establishes every aspect of biological function.

Toxins, pathogen proteins, and other challenging targets

For toxins and pathogen-associated proteins, the intended outcome is especially important. A diagnostic binder needs reliable recognition in the relevant sample, while a neutralizing binder must also interfere with a defined biological activity. Binding alone does not demonstrate neutralization, protection, or diagnostic performance, so I would set separate criteria for affinity, specificity, and functional testing.

Safety and antigen handling should also be considered during project planning. Depending on the target, teams may choose a non-toxic fragment, an inactivated preparation, or another suitable representation, subject to their biosafety procedures. For veterinary pathogens, it is also useful to decide whether the desired binder should recognize one strain, multiple strains, or a conserved region across related organisms.

For more information, please visit NBbiolab.

How Target Type Changes the Discovery Workflow

Nanobody discovery commonly involves generating or selecting a VHH repertoire, screening candidates against a target, and validating selected binders. VHH domains are typically about 12–15 kDa, but their small size does not eliminate the need for careful antigen design or functional testing. The route may involve an immune repertoire or a synthetic library, depending on the project’s goals, timeline, available antigen, and desired diversity.

Choose antigen presentation before choosing the screening route

First, define the target construct and its relevant state. Next, choose a presentation format that supports that state: purified protein for many soluble targets, cells or membrane-compatible preparations for surface targets, and assembled material for complexes when available. Then plan counter-screens and controls that address likely false positives, such as affinity tags, carrier proteins, host-cell components, or unrelated cells.

For an immune-library approach, antigen quality influences the response that can be selected; for a synthetic-library approach, screening conditions and library design influence which candidates are recovered. Neither route is automatically superior for every target. I would compare them against practical project requirements, including target accessibility, desired species cross-reactivity, and whether functional activity is essential.

Build validation around the end use

Discovery-stage binding is a starting point, not a complete product qualification. For a veterinary diagnostic reagent, validation may need to address signal-to-background, sample matrix effects, and cross-reactivity with related organisms or host proteins. For a research binder, reproducible binding and performance in the intended assay may be the primary goals. For a therapeutic research program, additional functional and developability assessments may be needed.

When the application is not yet fixed, I recommend agreeing on a small set of decision criteria before screening begins. These might include recognition of the native target, species coverage, assay compatibility, and a minimum level of functional evidence appropriate to the intended use. Testing conditions such as pH 7.2–7.4 may be relevant for some physiological assays, but the correct range depends on the assay design and sample environment.

Common Strategy Mismatches to Avoid

Using a convenient fragment without checking relevance: A fragment may omit an epitope or expose a surface that is inaccessible in the native protein.
Equating binding with function: Binding data do not, by themselves, prove neutralization, agonism, inhibition, or diagnostic accuracy.
Ignoring the final sample: Performance against purified antigen may not predict performance in serum, tissue, or another veterinary sample matrix.
Skipping negative controls: Controls help identify recognition of tags, carriers, host-cell proteins, and unrelated cells.
Leaving species requirements undefined: A project should state whether it needs species-specific binding or cross-reactivity across veterinary species or pathogen variants.

Choosing a Discovery Partner

A useful supplier discussion should cover more than the target name. I suggest sharing the target sequence or construct, available antigen formats, relevant species, intended application, and any known assay constraints. Ask how the provider plans to represent the target, what counter-screens are proposed, how candidates will be characterized, and which materials and data are included in the deliverables.

At NBbiolab, we approach custom nanobody discovery by aligning the target format and screening plan with the intended research or veterinary application. Project scope should be agreed in advance, including antigen requirements, validation assays, sequence and sample deliverables, and any additional characterization requested. Because target difficulty and available materials vary, feasibility, schedule, and cost should be assessed for the specific project rather than assumed from a generic workflow.

Conclusion: Match the Strategy to the Target and Use

The best nanobody discovery strategy is the one that presents the target in a biologically relevant form and tests candidates in conditions that reflect their intended use. Soluble proteins often support purified-antigen screening, while membrane proteins, complexes, toxins, and pathogen targets may require specialized presentation, counter-screening, or functional validation. In every case, define whether the goal is binding, detection, or biological activity before selecting the workflow.

As a next step, prepare a project brief with the target form, veterinary species, sample type, intended assay, and desired cross-reactivity or function. Share that information with a discovery partner and ask for a target-specific plan covering antigen preparation, screening controls, validation, and deliverables. This practical alignment gives your team a clearer basis for evaluating candidates and deciding whether a custom nanobody discovery project is the right fit.